Datasheet for ABIN7448172

SSTR2 Protein-VLP (AA 1-369)

2 Images

Go to Product page

Overview

Quantity:	100 µg
Target:	SSTR2
Protein Characteristics:	AA 1-369
Origin:	Human
Source:	HEK-293 Cells
Protein Type:	VLP
Biological Activity:	Active
Application:	ELISA, Immunogen (Imm), Functional Studies (Func), Surface Plasmon Resonance (SPR)

Product Details

Purpose:	Human SSTR2 Protein-VLP
Sequence:	Met1-Ile369
Characteristics:	Recombinant Human SSTR2 Protein-VLP is expressed from HEK293.It contains Met1-Ile369.
Purity:	> 95 % as determined by HPLC
Sterility:	0.22 µm filtered
Endotoxin Level:	Less than 1EU per µg by the LAL method.
Biological Activity Comment:	Immobilized Human SSTR2 VLP at 5µg/ml on the plate (100µl/Well). Dose response curve for Anti-SSTR2 Antibody, hFc Tag with the EC50 of 32.8ng/ml determined by ELISA.

Target Details

Target:	SSTR2
Alternative Name:	SSTR2 (SSTR2 Products)
Background:	Somatostatin receptor (SSTR) 2, widely expressed in meningioma, is a G-protein-coupled receptor and can be activated by somatostatin or its synthetic analogs. SSTR2 is therefore extensively studied as a marker and target for the diagnosis and treatment of meningioma.
Molecular Weight:	42.7 kDa.

Application Details

Application Notes:	• Antibody Discovery: Immunization, Screening, Functional Characterization • Affinity determination: ELISA, SPR • In vivo pharmacokinetic analysis • CMC method development • CAR-T Positive Rate Detection • Blood sample determination: ELISA
Comment:	Virus-like particles (VLPs) are formed from the outer capsid protein of a virus and are tiny nanoparticles formed by the automatic assembly of one or more capsid proteins. VLPs do not contain viral infectious genomes, so they are relatively safe during production operations. The SAMS™ protein engineering platform has been used to express a series of biotinylated, non-biotinylated, and fluorescently-labeled VLP-displayed antigens. They are suitable for SPR, ELISA, CAR-T positive rate detection, and other experimental scenarios. Virus-Like Particles (VLPs) are highly immunogenic, meaning that they can elicit a strong immune response in the host. VLPs are recognized by the immune system and are taken up by antigen-presenting cells (APCs) such as dendritic cells. Once taken up by APCs, VLPs are processed and presented to T cells, which can trigger the activation of B cells to produce antibodies against the displayed antigen. Because VLPs resemble the structure and composition of native viruses, they are highly effective at inducing both humoral and cellular immune responses. Generally, VLPs range in size from approximately 20 to 200 nanometers (nm). Compared to a cell-based immunization approach, their smaller size can optimize the immune response to target the specific antigen displayed on the surface of the engineered VLPs.
Restrictions:	For Research Use only

Handling

Format:	Liquid
Buffer:	Supplied as 0.22μm filtered solution in PBS (pH 7.4). Notice: If you need it for immunization, Do Not use any adjuvant.
Storage:	-80 °C
Storage Comment:	Valid for 12 months from date of receipt when stored at -80°C., Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Expiry Date:	12 months

Images



Size-exclusion chromatography-High Pressure Liquid Chromatography

Image 1. The purity of Human SSTR2 VLP is greater than 95 % as determined by SEC-HPLC.



ELISA

Image 2. Immobilized Human SSTR2 VLP at 5 μg/mL on the plate (100 μL/Well). Dose response curve for Anti-SSTR2 Antibody, hFc Tag with the EC50 of 32.8 ng/mL determined by ELISA.